Literature DB >> 8554923

Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline.

J P Roux1, M E Arlot, E Gineyts, P J Meunier, P D Delmas.   

Abstract

Measuring bone resorption accurately by histomorphometry of bone biopsies is a challenge. Several techniques have been proposed including the measurement of eroded surfaces and resorption depth, but they have not been compared between themselves nor with biochemical assessment of bone resorption. In addition, there is a need for a rapid method that could be used more routinely. We describe here an automatic interactive method using a color analyzer (Visiolab, BIOCOM, France) with a specific software for the evaluation of erosion depth, eroded volume, eroded surface, osteoclast number, and surface. Thirty transiliac undecalcified bone biopsies stained with Goldner's trichrome were used in this study, taken from subjects suffering from osteoporosis or primary hyperparathyroidism. At the time of the biopsy a 2 h fasting morning urine sample was collected for measurement by HPLC of total deoxypyridinoline, the most sensitive marker of bone resorption. There was a highly significant correlation between maximum erosion depth measured directly and the one calculated according to the count of eroded lamellae (E. F. Eriksen, et al. Metab Bone Dis Relat Res 5:243-252; 1984) (r = 0.76; p = 0.0001). A significant correlation was found between urinary deoxypyridinoline and eroded volume/bone volume in cancellous and endocortical bone measured with the automatic interactive technique (r = 0.48; p = 0.007). In contrast, other histological indexes of bone resorption did not correlate with urinary deoxypyridinoline. The volume of resorption cavities appears to be the most valid index of bone resorption rate as it was correlated with the urinary excretion of total deoxypyridinoline.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554923     DOI: 10.1016/s8756-3282(95)00174-3

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 2.  From histology to micro-CT: Measuring and modeling resorption cavities and their relation to bone competence.

Authors:  Jef Vanderoost; G Harry van Lenthe
Journal:  World J Radiol       Date:  2014-09-28

3.  Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.

Authors:  J J Stepan; D B Burr; J Li; Y L Ma; H Petto; A Sipos; H Dobnig; A Fahrleitner-Pammer; D Michalská; I Pavo
Journal:  Osteoporos Int       Date:  2010-02-05       Impact factor: 4.507

4.  Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.

Authors:  Matthew R Allen; Antonia M Erickson; Xiang Wang; David B Burr; R Bruce Martin; Scott J Hazelwood
Journal:  Calcif Tissue Int       Date:  2009-12-02       Impact factor: 4.333

5.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

Authors:  P Szulc; P D Delmas
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

Review 6.  Pharmacology of intra-articular triamcinolone.

Authors:  Justin Scherer; K D Rainsford; Colin A Kean; Walter F Kean
Journal:  Inflammopharmacology       Date:  2014-05-14       Impact factor: 4.473

Review 7.  Interest of Bone Histomorphometry in Bone Pathophysiology Investigation: Foundation, Present, and Future.

Authors:  Pascale Chavassieux; Roland Chapurlat
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

8.  Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline.

Authors:  R P Hesley; K A Shepard; D K Jenkins; B L Riggs
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

9.  Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.

Authors:  Pascale Chavassieux; Nathalie Portero-Muzy; Jean Paul Roux; Stéphane Horlait; David W Dempster; Andrea Wang; Rachel B Wagman; Roland Chapurlat
Journal:  J Bone Miner Res       Date:  2019-01-02       Impact factor: 6.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.